Exscientia Plc (EXAI) - News Archive

In a significant stride for collaborative drug development, Exscientia plc headquartered in , England and publicly traded on Nasdaq as EXAI has announced the progression of two drug development programs in partnership w...

In a significant stride for drug discovery innovation, Exscientia plc (Nasdaq: EXAI) has successfully advanced two discovery programmes in its collaboration with global biopharmaceutical giant Sanofi. The announcement c...

In a groundbreaking announcement today, Exscientia plc (Nasdaq: EXAI) underscored its commitment to revolutionizing cancer treatment by unveiling new preclinical data concerning its precision-engineered LSD1 (lysine-spe...

Summary Exscientia plc, a leader in artificial intelligence-driven drug discovery, is poised to present significant new preclinical findings concerning its LSD1 and MALT1 inhibitors at the upcoming 36th EORTC-NCI-AACR (...

Exscientia Acquires Full Rights to Potential Best-in-Class CDK7 Inhibitor Ahead of Phase 1 Dose Escalation Data ReadoutOXFORD, England - Exscientia, a leading artificial intelligence (AI) driven biopharmaceutical compan...

: Exscientia plc (Nasdaq: EXAI), a leading AI-driven drug discovery company based in Oxford, England, has announced a significant expansion of its collaboration with Amazon Web Services (AWS). The partnership involves l...

Legal Storm Looms Over Exscientia: Securities Class Actions Highlight Investor Concerns New York, June 13, 2024 The legal troubles for Exscientia p.l.c. (NASDAQ: EXAI) are intensifying as both Pomerantz LLP and Gainey M...

Two prominent law firms have announced class action lawsuits against Exscientia p.l.c (NASDAQ: EXAI), urging investors who purchased securities between March 23, 2022, and February 12, 2024, to seek legal counsel before...

In a significant development for investors, Pomerantz LLP has announced the filing of a class action lawsuit against Exscientia p.l.c. (NASDAQ: EXAI) and certain of its officers. This lawsuit, which has been officially...

: The legal strains often overshadow pharmaceutical breakthroughs in the biopharmaceutical industry. The broad spectrum of legalities forms a labyrinth where corporate action, investor rights, and public protection coll...